Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial

Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel abla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Arrhythmia and electrophysiology 2020-03, Vol.13 (3), p.e007917-e007917
Hauptverfasser: Turagam, Mohit K., Petru, Jan, Neuzil, Petr, Kakita, Ken, Kralovec, Stepan, Harari, David, Phillips, Patrick, Piazza, Danielo, Whang, William, Dukkipati, Srinivas R., Reddy, Vivek Y.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e007917
container_issue 3
container_start_page e007917
container_title Circulation. Arrhythmia and electrophysiology
container_volume 13
creator Turagam, Mohit K.
Petru, Jan
Neuzil, Petr
Kakita, Ken
Kralovec, Stepan
Harari, David
Phillips, Patrick
Piazza, Danielo
Whang, William
Dukkipati, Srinivas R.
Reddy, Vivek Y.
description Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel ablation system employs low intensity collimated ultrasound (LICU)-guided anatomic mapping and robotic ablation to isolate PVs. In this first-in-human, single-center, multioperator trial, VALUE trial (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determine its safety, effectiveness in PV isolation, and freedom from recurrent atrial arrhythmias. In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and ablation was performed under robotic control along an operator-defined lesion path. The LICU system software advanced over the course of the study: the last 13 patients were ablated with enhanced software. Acute PV isolation was achieved in 98% of PVs-using LICU-only in 77.3% (153/198) of PVs and requiring touch-up with a standard radiofrequency ablation catheter in 22.7% (45/198) PVs. The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software. Freedom from atrial arrhythmia recurrence was 79.6% (39/49 patients) at 12 months or 92.3% (12/13 patients) with the enhanced software. Major adverse events occurred in 3 patients (5.8%): one had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-segment elevation from air-embolism, without sequelae. In this first-in-human study, low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhancements. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03639597.
doi_str_mv 10.1161/CIRCEP.119.007917
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2378885580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2378885580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2985-9d69fdbaea66fa4e32d81bc7caa239380b332c3bfa63b7b59a0f3f7bf55e925a3</originalsourceid><addsrcrecordid>eNo9kc1u2zAQhIWiRfPTPEAvBY-9KFmS-iF7Ewy7MWA0RRvnKiwlMlYrkSlJIchb9JFDQ0kOi53DN4PFTpZ9pnBJaUWvVttfq_XPpOUlQC1p_S47pbKgOQdRvH_VtJAn2VkIfwAqKmj1MTvhDGrBK3aa_W_m6CaMuic_nO2cjdhFsh-jx-Bm25PthPeDvSeYdKNGjIOz5PdTiHoixnkSD5rceo1x0jYSZ0gT_YAj2QzKD-PCfyM3c-zcpMMRODo2gw8xH2x-PU9oyV2z269TTDJ-yj4YHIO-eNnn2X6zvl1d57ub79tVs8s7JkWZy76SpleosaoMFpqzXlDV1R0i45ILUJyzjiuDFVe1KiWC4aZWpiy1ZCXy8-zrkvvg3b9Zh9hOQ-h0uthqN4eW8VoIUZYCEkoXtPMuBK9N--CHCf1TS6E9FtEuRSQt26WI5PnyEj-rSfdvjtfPJ6BYgEc3Ru3D33F-1L49aBzjoQXKeV1InjNgABwA8jRQ8meNOZW8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2378885580</pqid></control><display><type>article</type><title>Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial</title><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Turagam, Mohit K. ; Petru, Jan ; Neuzil, Petr ; Kakita, Ken ; Kralovec, Stepan ; Harari, David ; Phillips, Patrick ; Piazza, Danielo ; Whang, William ; Dukkipati, Srinivas R. ; Reddy, Vivek Y.</creator><creatorcontrib>Turagam, Mohit K. ; Petru, Jan ; Neuzil, Petr ; Kakita, Ken ; Kralovec, Stepan ; Harari, David ; Phillips, Patrick ; Piazza, Danielo ; Whang, William ; Dukkipati, Srinivas R. ; Reddy, Vivek Y.</creatorcontrib><description>Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel ablation system employs low intensity collimated ultrasound (LICU)-guided anatomic mapping and robotic ablation to isolate PVs. In this first-in-human, single-center, multioperator trial, VALUE trial (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determine its safety, effectiveness in PV isolation, and freedom from recurrent atrial arrhythmias. In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and ablation was performed under robotic control along an operator-defined lesion path. The LICU system software advanced over the course of the study: the last 13 patients were ablated with enhanced software. Acute PV isolation was achieved in 98% of PVs-using LICU-only in 77.3% (153/198) of PVs and requiring touch-up with a standard radiofrequency ablation catheter in 22.7% (45/198) PVs. The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software. Freedom from atrial arrhythmia recurrence was 79.6% (39/49 patients) at 12 months or 92.3% (12/13 patients) with the enhanced software. Major adverse events occurred in 3 patients (5.8%): one had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-segment elevation from air-embolism, without sequelae. In this first-in-human study, low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhancements. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03639597.</description><identifier>ISSN: 1941-3149</identifier><identifier>EISSN: 1941-3084</identifier><identifier>DOI: 10.1161/CIRCEP.119.007917</identifier><identifier>PMID: 32078362</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><ispartof>Circulation. Arrhythmia and electrophysiology, 2020-03, Vol.13 (3), p.e007917-e007917</ispartof><rights>American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2985-9d69fdbaea66fa4e32d81bc7caa239380b332c3bfa63b7b59a0f3f7bf55e925a3</cites><orcidid>0000-0002-5638-4993</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32078362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turagam, Mohit K.</creatorcontrib><creatorcontrib>Petru, Jan</creatorcontrib><creatorcontrib>Neuzil, Petr</creatorcontrib><creatorcontrib>Kakita, Ken</creatorcontrib><creatorcontrib>Kralovec, Stepan</creatorcontrib><creatorcontrib>Harari, David</creatorcontrib><creatorcontrib>Phillips, Patrick</creatorcontrib><creatorcontrib>Piazza, Danielo</creatorcontrib><creatorcontrib>Whang, William</creatorcontrib><creatorcontrib>Dukkipati, Srinivas R.</creatorcontrib><creatorcontrib>Reddy, Vivek Y.</creatorcontrib><title>Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial</title><title>Circulation. Arrhythmia and electrophysiology</title><addtitle>Circ Arrhythm Electrophysiol</addtitle><description>Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel ablation system employs low intensity collimated ultrasound (LICU)-guided anatomic mapping and robotic ablation to isolate PVs. In this first-in-human, single-center, multioperator trial, VALUE trial (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determine its safety, effectiveness in PV isolation, and freedom from recurrent atrial arrhythmias. In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and ablation was performed under robotic control along an operator-defined lesion path. The LICU system software advanced over the course of the study: the last 13 patients were ablated with enhanced software. Acute PV isolation was achieved in 98% of PVs-using LICU-only in 77.3% (153/198) of PVs and requiring touch-up with a standard radiofrequency ablation catheter in 22.7% (45/198) PVs. The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software. Freedom from atrial arrhythmia recurrence was 79.6% (39/49 patients) at 12 months or 92.3% (12/13 patients) with the enhanced software. Major adverse events occurred in 3 patients (5.8%): one had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-segment elevation from air-embolism, without sequelae. In this first-in-human study, low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhancements. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03639597.</description><issn>1941-3149</issn><issn>1941-3084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kc1u2zAQhIWiRfPTPEAvBY-9KFmS-iF7Ewy7MWA0RRvnKiwlMlYrkSlJIchb9JFDQ0kOi53DN4PFTpZ9pnBJaUWvVttfq_XPpOUlQC1p_S47pbKgOQdRvH_VtJAn2VkIfwAqKmj1MTvhDGrBK3aa_W_m6CaMuic_nO2cjdhFsh-jx-Bm25PthPeDvSeYdKNGjIOz5PdTiHoixnkSD5rceo1x0jYSZ0gT_YAj2QzKD-PCfyM3c-zcpMMRODo2gw8xH2x-PU9oyV2z269TTDJ-yj4YHIO-eNnn2X6zvl1d57ub79tVs8s7JkWZy76SpleosaoMFpqzXlDV1R0i45ILUJyzjiuDFVe1KiWC4aZWpiy1ZCXy8-zrkvvg3b9Zh9hOQ-h0uthqN4eW8VoIUZYCEkoXtPMuBK9N--CHCf1TS6E9FtEuRSQt26WI5PnyEj-rSfdvjtfPJ6BYgEc3Ru3D33F-1L49aBzjoQXKeV1InjNgABwA8jRQ8meNOZW8</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Turagam, Mohit K.</creator><creator>Petru, Jan</creator><creator>Neuzil, Petr</creator><creator>Kakita, Ken</creator><creator>Kralovec, Stepan</creator><creator>Harari, David</creator><creator>Phillips, Patrick</creator><creator>Piazza, Danielo</creator><creator>Whang, William</creator><creator>Dukkipati, Srinivas R.</creator><creator>Reddy, Vivek Y.</creator><general>American Heart Association, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5638-4993</orcidid></search><sort><creationdate>20200301</creationdate><title>Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial</title><author>Turagam, Mohit K. ; Petru, Jan ; Neuzil, Petr ; Kakita, Ken ; Kralovec, Stepan ; Harari, David ; Phillips, Patrick ; Piazza, Danielo ; Whang, William ; Dukkipati, Srinivas R. ; Reddy, Vivek Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2985-9d69fdbaea66fa4e32d81bc7caa239380b332c3bfa63b7b59a0f3f7bf55e925a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turagam, Mohit K.</creatorcontrib><creatorcontrib>Petru, Jan</creatorcontrib><creatorcontrib>Neuzil, Petr</creatorcontrib><creatorcontrib>Kakita, Ken</creatorcontrib><creatorcontrib>Kralovec, Stepan</creatorcontrib><creatorcontrib>Harari, David</creatorcontrib><creatorcontrib>Phillips, Patrick</creatorcontrib><creatorcontrib>Piazza, Danielo</creatorcontrib><creatorcontrib>Whang, William</creatorcontrib><creatorcontrib>Dukkipati, Srinivas R.</creatorcontrib><creatorcontrib>Reddy, Vivek Y.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation. Arrhythmia and electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turagam, Mohit K.</au><au>Petru, Jan</au><au>Neuzil, Petr</au><au>Kakita, Ken</au><au>Kralovec, Stepan</au><au>Harari, David</au><au>Phillips, Patrick</au><au>Piazza, Danielo</au><au>Whang, William</au><au>Dukkipati, Srinivas R.</au><au>Reddy, Vivek Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial</atitle><jtitle>Circulation. Arrhythmia and electrophysiology</jtitle><addtitle>Circ Arrhythm Electrophysiol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>13</volume><issue>3</issue><spage>e007917</spage><epage>e007917</epage><pages>e007917-e007917</pages><issn>1941-3149</issn><eissn>1941-3084</eissn><abstract>Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel ablation system employs low intensity collimated ultrasound (LICU)-guided anatomic mapping and robotic ablation to isolate PVs. In this first-in-human, single-center, multioperator trial, VALUE trial (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determine its safety, effectiveness in PV isolation, and freedom from recurrent atrial arrhythmias. In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and ablation was performed under robotic control along an operator-defined lesion path. The LICU system software advanced over the course of the study: the last 13 patients were ablated with enhanced software. Acute PV isolation was achieved in 98% of PVs-using LICU-only in 77.3% (153/198) of PVs and requiring touch-up with a standard radiofrequency ablation catheter in 22.7% (45/198) PVs. The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software. Freedom from atrial arrhythmia recurrence was 79.6% (39/49 patients) at 12 months or 92.3% (12/13 patients) with the enhanced software. Major adverse events occurred in 3 patients (5.8%): one had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-segment elevation from air-embolism, without sequelae. In this first-in-human study, low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhancements. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03639597.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>32078362</pmid><doi>10.1161/CIRCEP.119.007917</doi><orcidid>https://orcid.org/0000-0002-5638-4993</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1941-3149
ispartof Circulation. Arrhythmia and electrophysiology, 2020-03, Vol.13 (3), p.e007917-e007917
issn 1941-3149
1941-3084
language eng
recordid cdi_proquest_miscellaneous_2378885580
source American Heart Association Journals; EZB-FREE-00999 freely available EZB journals
title Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T08%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Automated%20Noncontact%20Ultrasound%20Imaging%20and%20Ablation%20System%20for%20the%20Treatment%20of%20Atrial%20Fibrillation:%20Outcomes%20of%20the%20First-in-Human%20VALUE%20Trial&rft.jtitle=Circulation.%20Arrhythmia%20and%20electrophysiology&rft.au=Turagam,%20Mohit%20K.&rft.date=2020-03-01&rft.volume=13&rft.issue=3&rft.spage=e007917&rft.epage=e007917&rft.pages=e007917-e007917&rft.issn=1941-3149&rft.eissn=1941-3084&rft_id=info:doi/10.1161/CIRCEP.119.007917&rft_dat=%3Cproquest_cross%3E2378885580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2378885580&rft_id=info:pmid/32078362&rfr_iscdi=true